Top Posts of 2013

It’s been a big year for pharma, with heavy weight debates in the US over biosimilars, momentum building in Antibody-drug Conjugate technology, and an upturn in investment and IPOs for biotech firms. So what has earned the most attention here at Total BioPharma over the past year? Well below is the list of the top 10 most read articles of …